Please assess the completion status of the following clinical trial:

Trial Title: Maraviroc as GVHD Prophylaxis in Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 5 years and \</= 40 years~* All diagnoses~* Peripheral blood stem cells, marrow or cord blood~* All conditioning regimens~* Patient must be planned to receive a calcineurin inhibitor (cyclosporine or tacrolimus) together with steroid, methotrexate or mycophenolate mofetil as GVHD prophylaxis.~Exclusion Criteria:~* Documented anaphylaxis to Maraviroc~* Ex vivo T-cell (type of white blood cell) depleted grafts~* Abnormal Alanine Aminotransferase (ALT) (\>/=10X ULN) on day -3. (Assessed at study enrollment and confirmed again prior to the first dose of maraviroc.)

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Maraviroc (Type: EXPERIMENTAL): Maraviroc administration will start on day -3 and will end on day +30 after stell cell transplant, making the total number of days of drug administration 34 days. Maraviroc will be administered twice daily orally or via enteral tube. Dosing of Maraviroc will be based on body surface area (starting with 100mg twice a day for BSA of 0.2 and up to 300mg twice a day for BSA greater than 1.73).

Based on this trial design, predict the completion outcome and termination type (if applicable).